Compare
InMode Ltd. vs Axogen, Inc. vs Outset Medical, Inc. vs LivaNova PLC
| Latest fiscal year | InMode Ltd. INMD | Axogen, Inc. AXGN | Outset Medical, Inc. OM | LivaNova PLC LIVN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $370.50M | $225.21M | $119.48M | $1.39B |
| Revenue growth (YoY) | -6.2% | +20.2% | +5.1% | +10.7% |
| Gross margin | 78.5% | 74.3% | 39.1% | 67.7% (computed) |
| Operating margin | 23.0% | -3.5% | -55.8% | 14.4% |
| Net margin | 25.3% | -7.0% | -68.3% | -17.5% |
| Net income | $93.83M | -$15.70M | -$81.65M | -$242.47M |
| EPS (Diluted) | $1.43 | -$0.34 | -$5.37 | -$4.45 |
| Operating cash flow | $85.26M | $812.0K | -$46.33M | $254.34M |
| Free cash flow | $84.28M | -$2.93M | -$47.12M | $173.29M |
| Cash & equivalents | $302.54M | $35.55M | $35.01M | $635.55M |
| Total assets | $766.43M | $221.69M | $264.50M | $2.61B |
| Total liabilities | $83.23M | $92.84M | $137.54M | $1.41B |
| Shareholders' equity | $683.20M | $128.85M | $126.95M | $1.20B |
| Return on year-end equity | 13.7% | -12.2% | -64.3% | -20.2% |
| Shares outstanding | 63.36M | 47.20M | 18.17M | 54.65M |
Revenue, most recent five fiscal years
| Fiscal year | InMode Ltd. | Axogen, Inc. | Outset Medical, Inc. | LivaNova PLC |
|---|---|---|---|---|
| Latest | $370.50M Ended 2025-12-31 | $225.21M Ended 2025-12-31 | $119.48M Ended 2025-12-31 | $1.39B Ended 2025-12-31 |
| 1 year earlier | $394.82M Ended 2024-12-31 | $187.34M Ended 2024-12-31 | $113.69M Ended 2024-12-31 | $1.25B Ended 2024-12-31 |
| 2 years earlier | $492.05M Ended 2023-12-31 | $159.01M Ended 2023-12-31 | $130.38M Ended 2023-12-31 | $1.15B Ended 2023-12-31 |
| 3 years earlier | $454.27M Ended 2022-12-31 | $138.58M Ended 2022-12-31 | $115.38M Ended 2022-12-31 | $1.02B Ended 2022-12-31 |
| 4 years earlier | $357.56M Ended 2021-12-31 | $127.36M Ended 2021-12-31 | $102.60M Ended 2021-12-31 | $1.04B Ended 2021-12-31 |